The JAK-STAT Signaling Pathway
Abnormal Proliferation
Interactions Between Signaling Pathways
Amplifying Signals via Enzymatic Cascade
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 8, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
David Vindrieux1, Arnaud Augert, Christophe A Girard
1Authors' Affiliations: Inserm U1052, Centre de Recherche en Cancérologie de Lyon; CNRS UMR5286; Centre Léon Bérard; Université de Lyon, Lyon; UMR8161, CNRS/Universités de Lille 1 et 2; Institut de Pharmacologie Moléculaire et Cellulaire, UMR7275, CNRS and Université de Nice-Sophia Antipolis, Valbonne; INSERM U916, Bergonié Cancer Institute, Université Bordeaux, Bordeaux; and Institut de Pathologie, CHRU, Faculté de Médecine, Université de Lille; INSERM U837, Jean-Pierre Aubert Research Center, Team 5, Lille; Department of Medicine, University of Washington, Seattle, Washington.
The phospholipase A2 receptor (PLA2R1) acts as a tumor suppressor by preventing oncogene-induced senescence escape. Its depletion promotes tumorigenesis, unexpectedly through activating the JAK2 pathway.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: